{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:09:37Z","timestamp":1786118977921,"version":"build-2736575974"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1097\/cco.0b013e32831369b2","type":"journal-article","created":{"date-parts":[[2008,10,7]],"date-time":"2008-10-07T03:08:59Z","timestamp":1223348939000},"page":"690-696","source":"Crossref","is-referenced-by-count":11,"title":["The use of second-generation thrombopoietic agents for chemotherapy-induced thrombocytopenia"],"prefix":"10.1097","volume":"20","author":[{"given":"Benjamin","family":"Levy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon E","family":"Arnason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James B","family":"Bussel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-14-20210128","first-page":"44","article-title":"The chemotherapy source book","author":"Perry","year":"2008"},{"key":"R2-14-20210128","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood.V82.5.1395.1395","article-title":"Oligodeoxynucleotides antisense to the proto-oncogene c-mpl specifically inhibit in vitro megakaryocytopoiesis","volume":"82","author":"Methia","year":"1993","journal-title":"Blood"},{"key":"R3-14-20210128","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood.V86.7.2516.2516","article-title":"The Mpl-ligand or thrombopoietin or megakaryocyte growth and differentiative factor has both direct proliferative and differentiative activities on human megakaryocyte progenitors","volume":"86","author":"Debili","year":"1995","journal-title":"Blood"},{"key":"R4-14-20210128","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1651-2227.1998.tb01227.x","article-title":"The Mpl ligand and platelet homeostasis","volume":"424","author":"Nichol","year":"1998","journal-title":"Acta Paediatr Suppl"},{"key":"R5-14-20210128","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1182\/blood.V93.9.2798","article-title":"Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy","volume":"93","author":"Somlo","year":"1999","journal-title":"Blood"},{"key":"R6-14-20210128","first-page":"3118","article-title":"Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer","volume":"89","author":"Basser","year":"1997","journal-title":"Blood"},{"key":"R7-14-20210128","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(96)04471-6","article-title":"Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer","volume":"348","author":"Basser","year":"1996","journal-title":"Lancet"},{"key":"R8-14-20210128","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1200\/JCO.2000.18.15.2852","article-title":"Enhancement of platelet recovery after myelosuppressive chemotherapy by recombinant human megakaryocyte growth and development factor in patients with advanced cancer","volume":"18","author":"Basser","year":"2000","journal-title":"J Clin Oncol"},{"key":"R9-14-20210128","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1056\/NEJM199702063360603","article-title":"Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer","volume":"336","author":"Fanucchi","year":"1997","journal-title":"N Engl J Med"},{"key":"R10-14-20210128","doi-asserted-by":"crossref","first-page":"364","DOI":"10.7326\/0003-4819-132-5-200003070-00005","article-title":"Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer","volume":"132","author":"Vadhan-Raj","year":"2000","journal-title":"Ann Intern Med"},{"key":"R11-14-20210128","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1182\/blood.V94.11.3694","article-title":"A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia","volume":"94","author":"Archimbaud","year":"1999","journal-title":"Blood"},{"key":"R12-14-20210128","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/sj.bmt.1702465","article-title":"Phase 1 study of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients after autologous peripheral blood progenitor cell (PBPC) transplantation","volume":"26","author":"Bolwell","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"R13-14-20210128","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1083-8791(00)70049-8","article-title":"A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation","volume":"6","author":"Nash","year":"2000","journal-title":"Biol Blood Marrow Transplant"},{"key":"R14-14-20210128","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1182\/blood.V95.8.2530","article-title":"A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia","volume":"95","author":"Schiffer","year":"2000","journal-title":"Blood"},{"key":"R15-14-20210128","first-page":"296a","article-title":"Pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) increased platelet counts (PLT) in patients (pts) with aplastic anemia (AA) and myelodysplastic syndrome (MDS) [abstract].","volume":"96","author":"Komatsu","year":"2000","journal-title":"Blood"},{"key":"R16-14-20210128","first-page":"707a","article-title":"Correction of thrombocytopenia and ineffective platelet production in patients with human immunodeficiency virus (HIV) by PEG-rHuMGDF therapy.","volume":"92","author":"Harker","year":"1998","journal-title":"Blood"},{"key":"R17-14-20210128","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1182\/blood.V100.2.728","article-title":"Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura","volume":"100","author":"Nomura","year":"2002","journal-title":"Blood"},{"key":"R18-14-20210128","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1182\/blood.V99.7.2599","article-title":"Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor","volume":"99","author":"Basser","year":"2002","journal-title":"Blood"},{"key":"R19-14-20210128","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/blood.V98.12.3241","article-title":"Thrombocytopenia caused by the development of antibodies to thrombopoietin","volume":"98","author":"Li","year":"2001","journal-title":"Blood"},{"key":"R20-14-20210128","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.clpt.2004.08.010","article-title":"Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand","volume":"76","author":"Wang","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"R21-14-20210128","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa054626","article-title":"AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP","volume":"355","author":"Bussel","year":"2006","journal-title":"N Engl J Med"},{"key":"R22-14-20210128","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1365-2141.2006.06339.x","article-title":"An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura","volume":"135","author":"Newland","year":"2006","journal-title":"Br J Haematol"},{"key":"R23-14-20210128","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0140-6736(08)60203-2","article-title":"Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial","volume":"371","author":"Kuter","year":"2008","journal-title":"Lancet"},{"key":"R24-14-20210128","first-page":"174a","article-title":"Long-term dosing of AMG 531 in thrombocytopenic patients with immune thrombocytopenic purpura: 2-year update [abstract number 568]","volume":"110","author":"Bussel","year":"2007","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"R26-14-20210128","first-page":"81a","article-title":"Phase 1\/2 study of AMG 531 in thrombocytopenic patients (pts) with low-risk myelodysplastic syndrome (MDS): update including extended treatment [abstract number 250]","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"R27-14-20210128","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1182\/blood-2006-11-057968","article-title":"Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist","volume":"109","author":"Jenkins","year":"2007","journal-title":"Blood"},{"key":"R28-14-20210128","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1056\/NEJMoa073255","article-title":"Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C","volume":"357","author":"McHutchison","year":"2007","journal-title":"N Engl J Med"},{"key":"R29-14-20210128","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1056\/NEJMoa073275","article-title":"Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura","volume":"357","author":"Bussel","year":"2007","journal-title":"N Engl J Med"},{"key":"R31-14-20210128","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1309\/09NP-3DFG-BLM9-E5LE","article-title":"Thrombopoietin administered during induction chemotherapy to patients with acute myeloid leukemia induces transient morphologic changes that may resemble chronic myeloproliferative disorders","volume":"117","author":"Douglas","year":"2002","journal-title":"Am J Clin Pathol"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CCO.0b013e32831369b2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:13:27Z","timestamp":1786036407000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001622-200811000-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0b013e32831369b2","relation":{},"ISSN":["1040-8746"],"issn-type":[{"value":"1040-8746","type":"print"}],"subject":[],"published":{"date-parts":[[2008,11]]}}}